{"id":61476,"date":"2025-06-24T07:03:50","date_gmt":"2025-06-24T05:03:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/"},"modified":"2025-06-24T07:03:50","modified_gmt":"2025-06-24T05:03:50","slug":"axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/","title":{"rendered":"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship"},"content":{"rendered":"
\n

FUJISAWA, Japan & BOSTON–(BUSINESS WIRE)–Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo<\/i> pharmacological evaluations of proprietary compounds developed by Superluminal using its unique predict-design-test architecture. In addition, the two companies collaborated on predictive ADME modeling, resulting in models that both companies can use as needed for their respective business purposes. Building on this foundation, the new project will combine Axcelead DDP\u2019s comprehensive drug discovery platform, including its pharma-originated research data, rich experienced medicinal chemistry, and in vitro\/in vivo pharmacology, with Superluminal\u2019s cutting-edge computational, AI\/ML, and structure-based drug design capabilities.<\/p>\n

\nThe collaboration aims to accelerate the discovery and development of innovative small-molecule therapeutics by jointly addressing multiple defined molecular targets with high unmet medical needs.<\/p>\n

\n\u201cAt Axcelead DDP, we have advanced our drug discovery platform, originally inherited from a top-tier pharmaceutical company, mainly through our own research, while strategically collaborating with external partners,\u201d said Kengo Okada, Ph.D., Representative Director and CEO of Axcelead DDP. \u201cBy applying this platform to support and accelerate Superluminal\u2019s drug discovery efforts targeting multiple mechanisms, we aim to contribute to the advancement of their pipeline and help address areas of high therapeutic demand. Our vision is to remain the drug discovery solution provider of choice for a diverse range of innovation-driven partners.\u201d<\/p>\n

\nCony D\u2019Cruz, CEO of Superluminal, added, \u201cWe are pleased with our partnership with Axcelead DDP. We appreciate the deep pharma experience and broad range of capabilities that enable Axcelead DDP to provide comprehensive drug discovery support to companies such as Superluminal.\u201d<\/p>\n

\nAbout Axcelead DDP<\/b><\/p>\n

\nAxcelead DDP is Japan\u2019s first drug discovery solution provider, established in July 2017 by inheriting the drug discovery platform from Takeda Pharmaceutical. Screening, medicinal chemistry, pharmacology\/biology, DMPK, and safety research functions with original compound library and large drug discovery database are integrated into one center with a state-of-the-art research base. Together with experienced drug discovery scientists, Axcelead DDP creates high-quality drug candidates rapidly. By leveraging these strengths, Axcelead DDP provides solutions to various challenges faced in the process, from exploratory research to clinical trials in drug discovery. For more information, please visit https:\/\/axcelead-us.com\/<\/a><\/p>\n

\nAbout Superluminal<\/b><\/p>\n

\nSuperluminal\u2019s platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico<\/i> prediction capability. The company\u2019s proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets. Based in Boston, the company is backed by a strong network of investors, including RA Capital, Insight Partners, NVIDIA, Catalio Capital, Eli Lilly and Company, and Gaingels. For more, visit www.superluminalrx.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nAxcelead Drug Discovery Partners, Inc.
\n
https:\/\/axcelead-us.com\/contact-us\/<\/a><\/p>\n

\nSuperluminal Medicines, Inc.
\n
Janine McCargo 6 Degrees
\n
jmccargo@6degreespr.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FUJISAWA, Japan & BOSTON–(BUSINESS WIRE)–Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61476","6":"format-standard","7":"category-industry"},"yoast_head":"\nAxcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FUJISAWA, Japan & BOSTON–(BUSINESS WIRE)–Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T05:03:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250623762266\/en\/2505743\/22\/ADDP_SuperL.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship\",\"datePublished\":\"2025-06-24T05:03:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/\"},\"wordCount\":544,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623762266\\\/en\\\/2505743\\\/22\\\/ADDP_SuperL.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/\",\"name\":\"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623762266\\\/en\\\/2505743\\\/22\\\/ADDP_SuperL.jpg\",\"datePublished\":\"2025-06-24T05:03:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623762266\\\/en\\\/2505743\\\/22\\\/ADDP_SuperL.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250623762266\\\/en\\\/2505743\\\/22\\\/ADDP_SuperL.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/","og_locale":"en_US","og_type":"article","og_title":"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship - Pharma Trend","og_description":"FUJISAWA, Japan & BOSTON–(BUSINESS WIRE)–Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-24T05:03:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250623762266\/en\/2505743\/22\/ADDP_SuperL.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship","datePublished":"2025-06-24T05:03:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/"},"wordCount":544,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250623762266\/en\/2505743\/22\/ADDP_SuperL.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/","url":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/","name":"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250623762266\/en\/2505743\/22\/ADDP_SuperL.jpg","datePublished":"2025-06-24T05:03:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250623762266\/en\/2505743\/22\/ADDP_SuperL.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250623762266\/en\/2505743\/22\/ADDP_SuperL.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/axcelead-ddp-and-superluminal-announce-the-intent-to-collaborate-on-drug-discovery-targeting-specific-molecular-mechanisms-continuing-a-productive-relationship\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61476"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61476\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}